Trial watch: Dendritic cell-based anticancer immunotherapy Review uri icon


MeSH Major

  • Apoptosis
  • Disease
  • Necrosis
  • Receptor-Interacting Protein Serine-Threonine Kinases


  • © 2017 Taylor & Francis Group, LLC Dendritic cell (DC)-based vaccines against cancer have been extensively developed over the past two decades. Typically DC-based cancer immunotherapy entails loading patient-derived DCs with an appropriate source of tumor-associated antigens (TAAs) and efficient DC stimulation through a so-called “maturation cocktail” (typically a combination of pro-inflammatory cytokines and Toll-like receptor agonists), followed by DC reintroduction into patients. DC vaccines have been documented to (re)activate tumor-specific T cells in both preclinical and clinical settings. There is considerable clinical interest in combining DC-based anticancer vaccines with T cell-targeting immunotherapies. This reflects the established capacity of DC-based vaccines to generate a pool of TAA-specific effector T cells and facilitate their infiltration into the tumor bed. In this Trial Watch, we survey the latest trends in the preclinical and clinical development of DC-based anticancer therapeutics. We also highlight how the emergence of immune checkpoint blockers and adoptive T-cell transfer-based approaches has modified the clinical niche for DC-based vaccines within the wide cancer immunotherapy landscape.

publication date

  • June 27, 2017



  • Review



  • eng

PubMed Central ID

  • PMC5543823

Digital Object Identifier (DOI)

  • 10.1080/2162402X.2017.1328341

PubMed ID

  • 28811970

Additional Document Info